奥拉西坦联合疏血通治疗原发性脑出血的临床研究_临床医学论文.docVIP

奥拉西坦联合疏血通治疗原发性脑出血的临床研究_临床医学论文 奥拉西坦联合疏血通治疗原发性脑出血的临床研究_临床医学论文 【摘要】 目的 探讨奥拉西坦联合疏血通治疗原发性脑出血的临床疗效。方法 将80例患者随机分为两组，治疗组44例，加用奥拉西坦和疏血通静脉滴注；对照组33例，加用胞磷胆碱钠静脉滴注，疗程均为21 d。以NIHSS计分评定神经功能缺失，以MMSE计分评定认知功能障碍，分析比较两组的治疗效果。结果 治疗组NIHSS评分和MMSE评分与治疗前相比较P＜0.01；与对照组相比较P＜0.01。其疗效优于对照组。结论 奥拉西坦联合疏血通治疗原发性脑出血疗效满意。 【关键词】 原发性脑出血；奥拉西坦；疏血通 【Abstract】 Objective To investigate the therapeutic efficacy of oxiracetam combined with shuxuetong in patients with primary intracranial hemorrhages.Methods Eighty cases with primary intracranial hemorrhages were randomly divided into two groups:44 cases were treated with oxiracetam combined with shuxuetong by intravenous infusing for 21days;36 cases were the conrtol group treated with citicoline sodium by intravenous infusing for 21days. To evaluate neural dysfunction with the scores of NIHSS and cognitive dysfunction with the scores of MMSE. To analyze the therapeutic efficacy compared with the control group. Results In these two groups, all of the scores of NIHSS and MMSE after the therapy were better than those before the therapy. And there was statistical significance difference (P＜0.01) .The scores of NIHSS and MMSE and MMSE after the therapy were better in therapeutic group than those in the control group .And there was statistical significance difference between the two groups (P＜0.05) .Conclusion The therapeutic efficacy of oxiracetam combined with shuxuetong in treating patients with primary intracranial hemorrhages was well. 【Key words】 primary intracanial hemorrhages,oxiracetam,shuxuetong 急性脑出血是神经内科的常见病、多发病，其病死率和致残率均极高。疏血通能够促进血肿吸收，减轻脑水肿，奥拉西坦能促进思维、记忆力和学习能力恢复，两者联合应用能改善神经功能缺失和认知功能障碍，现报告如下。 1 资料与方法 1．1 临床资料 2007年4月—2008年2月收治急性脑出血患者80例，其中男44例，女36例，年龄42～72岁。随机分为治疗组和对照组各40例,两组一般资料具有可比性。研究期间无病例脱落或剔除，两组在年龄、性别、体重、文化程度（均具有初中以上文化水平）、发病时间、既往病史、心率、血压、系统检查、发病情况等均没有明显差异（P＜0.05）。 1．2 诊断标准 依据第四届全国脑血管病会议制定的诊断标准［１］，并经脑CT或MRI 扫描证实，纳入标准：①首次发病或既往发病但未留肢体瘫痪者；②意识清醒或轻度嗜睡；③无活动性出血倾向，治疗前化验红细胞（RBC）、血小板计数（PLT）、出血时间（BT）、凝血时间（CT）、凝血酶原时间（PT）、大便隐血试验（OB）均正常。神经功能缺损评分，具有不同程度的